Novel approaches for the treatment of ventricular tachycardia  

作　　者：Michael Spartalis Eleftherios Spartalis Eleni Tzatzaki Diamantis I Tsilimigras Demetrios Moris Christos Kontogiannis Efthimios Livanis Dimitrios C Iliopoulos Vassilis Voudris George N Theodorakis 

机构地区：[1]ESC Working Group on Cardiac Cellular Electrophysiology,Sophia Antipolis Cedex 06903,France [2]Division of Cardiology,Onassis Cardiac Surgery Center,Athens 17674,Greece [3]Laboratory of Experimental Surgery and Surgical Research,University of Athens Medical School,Athens 11527,Greece [4]Department of Surgery,Duke University,Durham,NC 27710,United States [5]Department of Clinical Therapeutics,“Alexandra”Hospital,University of Athens,Athens 11528,Greece

出　　处：《World Journal of Cardiology》2018年第7期52-59,共8页世界心脏病学杂志（英文版）（电子版）

摘　　要：Ventricular tachycardia(VT) is a crucial cause of sudden cardiac death(SCD) and a primary cause of mortality and morbidity in patients with structural cardiac disease. VT includes clinical disorders varying from benign to lifethreatening. Most life-threatening episodes are correlated with coronary artery disease, but the risk of SCD varies in certain populations, with various underlying heart conditions, specific family history, and genetic variants. The targets of VT management are symptom alleviation, improved quality of life, reduced implantable cardioverter defibrillator shocks, prevention of reduction of left ventricular function, reduced risk of SCD, and improved overall survival. Antiarrhythmic drug therapy and endocardial catheter ablation remains the cornerstone of guideline-endorsed VT treatment strategies in patients with structural cardiac abnormalities. Novel strategies such as epicardial ablation, surgical cryoablation, transcoronary alcohol ablation, pre-procedural imaging, and stereotactic ablative radiotherapy are an appealing area of res-earch. In this review, we gathered all recent advances in innovative therapies as well as experimental evidence focusing on different aspects of VT treatment that could be significant for future favorable clinical applications.Ventricular tachycardia(VT) is a crucial cause of sudden cardiac death(SCD) and a primary cause of mortality and morbidity in patients with structural cardiac disease. VT includes clinical disorders varying from benign to lifethreatening. Most life-threatening episodes are correlated with coronary artery disease, but the risk of SCD varies in certain populations, with various underlying heart conditions, specific family history, and genetic variants. The targets of VT management are symptom alleviation, improved quality of life, reduced implantable cardioverter defibrillator shocks, prevention of reduction of left ventricular function, reduced risk of SCD, and improved overall survival. Antiarrhythmic drug therapy and endocardial catheter ablation remains the cornerstone of guideline-endorsed VT treatment strategies in patients with structural cardiac abnormalities. Novel strategies such as epicardial ablation, surgical cryoablation, transcoronary alcohol ablation, pre-procedural imaging, and stereotactic ablative radiotherapy are an appealing area of res-earch. In this review, we gathered all recent advances in innovative therapies as well as experimental evidence focusing on different aspects of VT treatment that could be significant for future favorable clinical applications.

关 键 词：VENTRICULAR TACHYCARDIA CATHETER ablation EPICARDIAL SUDDEN cardiac death NOVEL techniques Substrate 

分 类 号：R[医药卫生]